Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Taste Dysfunctions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Ministry of Health, Saudi Arabia
- Target Recruit Count
- 22
- Registration Number
- NCT05104424
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 679
- Registration Number
- NCT05013229
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇺🇸Andres Garcia-Zuniga, MD, P.A, Laredo, Texas, United States
🇫🇷Centre de Recherche Clinique Portes Du Sud, Venissieux, France
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Conditions
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04880850
- Locations
- 🇺🇸
UT Southwestern Med Cntr, Dallas, Texas, United States
🇯🇵Noritake Clinic, Ushiku-shi, Ibaraki, Japan
🇺🇸Amarillo Med Spec LLP, Amarillo, Texas, United States
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04848480
- Locations
- 🇯🇵
Yuri Ono Clinic, Sapporo-shi, Hokkaido, Japan
🇬🇧Churchill Hospital, Oxford, United Kingdom
🇬🇧Lister Hospital, Stevenage, United Kingdom
Fast-Acting Insulin Aspart and Insulin Pump Settings
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Kirsten Nørgaard
- Target Recruit Count
- 40
- Registration Number
- NCT04620967
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 331
- Registration Number
- NCT04588259
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, ChongQing, Chongqing, China
🇨🇳Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳Nanjing Jiangning Hospital, Nanjing, Jiangsu, China
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT04538352
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 137
- Registration Number
- NCT04460326
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Mountain Diabetes and Endocrine Center
- Target Recruit Count
- 59
- Registration Number
- NCT04409587
- Locations
- 🇺🇸
Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Geropharm
- Target Recruit Count
- 26
- Registration Number
- NCT04184466
- Locations
- 🇷🇺
Endocrinology Research Centre, Moscow, Russian Federation
🇷🇺Almazov National Medical Research Centre, Saint Petersburg,, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.